|1.||Arai, Yukinori: 5 articles (01/2009 - 08/2002)|
|2.||Smith, Neila: 4 articles (01/2009 - 06/2006)|
|3.||Blevins, Lewis S: 3 articles (11/2013 - 10/2010)|
|4.||Dhar, Rajat: 3 articles (12/2012 - 01/2009)|
|5.||Goldsmith, Steven R: 3 articles (12/2011 - 05/2005)|
|6.||Miyata, Keiji: 3 articles (01/2009 - 01/2005)|
|7.||Fujimori, Akira: 3 articles (01/2009 - 01/2005)|
|8.||Sasamata, Masao: 3 articles (01/2009 - 01/2005)|
|9.||Ghali, Jalal K: 3 articles (01/2009 - 06/2006)|
|10.||Wada, Koh-ichi: 3 articles (01/2007 - 08/2002)|
01/01/2008 - "The data reveal that conivaptan is useful in the management of significant hyponatremia. "
01/01/2009 - "Oral conivaptan was effective in increasing serum [Na] in patients with euvolemic or hypervolemic hyponatremia and had a favorable safety profile."
01/01/2009 - "Intermittent dosing of conivaptan was effective in increasing free water excretion and correcting hyponatremia in neurologically ill patients. "
07/01/2007 - "Conivaptan: new treatment for hyponatremia."
09/01/2013 - "To review the literature evaluating the clinical safety and efficacy of conivaptan in the management of hyponatremia in a neurologic and neuro-surgical adult patient population. "
02/26/1997 - "YM087 may be useful for the treatment of patients with congestive heart failure, renal diseases and water-retaining diseases."
06/15/2010 - "Multiple trials have evaluated conivaptan for the treatment of heart failure. "
07/01/2009 - "h/mL. The results of this study suggest that the pharmacokinetics of conivaptan 20 and 40 mg/d do not differ by volume status or the presence or absence of congestive heart failure."
09/01/2009 - "Conivaptan: promise of treatment in heart failure."
07/01/2009 - "No apparent differences in plasma conivaptan concentrations measured at 0.5 or 96 hours were observed between patients with euvolemic or hypervolemic hypona-tremia or between patients with or without congestive heart failure. "
|3.||Brain Injuries (Brain Injury)
06/01/2011 - "We hypothesized that administration of conivaptan to normonatremic patients with traumatic brain injury (TBI) is safe and could reduce intracranial pressure (ICP). "
12/01/2012 - "Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury."
02/01/2011 - "We evaluated the effect of a bolus of conivaptan on ICP in a patient with hyponatremia after traumatic brain injury (TBI). "
02/01/2011 - "A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury."
06/01/2011 - "Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury."
|4.||Body Weight (Weight, Body)
10/01/2008 - "Decreases in mean body weight with conivaptan 40 and 80 mg/d ( approximately 1-2 kg) paralleled the increases in urine output but did not reach statistical significance. "
01/10/2005 - "Conivaptan (0.3 mg/kg i.v.) significantly reduced right ventricular systolic pressure, left ventricular end-diastolic pressure, lung/body weight and right atrial pressure in myocardial infarction rats. "
06/01/2003 - "We assessed the aquaretic efficacy of 10-day chronic oral administration of Conivaptan (0.5mg/kg body weight (bw)) in cirrhotic rats with hyponatremia and water retention. "
07/01/2003 - "Vasopressin also appears to adversely effect hemodynamics and cardiac remodeling, while potentiating the effects of norepinephrine and angiotensin II. The selective V(2) and dual V(1a)/V(2) receptor antagonists tolvaptan and conivaptan, respectively, substantially increase free water excretion and plasma osmolality, reduce body weight, improve symptoms of congestion, and moderately increase serum sodium concentrations in patients with heart failure who present with symptoms of fluid overload. "
01/01/2014 - "Treatment with conventional anti-edema therapy was initiated with no significant clinical response after which conivaptan; a mixed vasopressin antagonist was started. "
10/01/1999 - "YM087 was effective in dogs with heart failure and in heart failure rats with hyponatremia and edema. "
01/01/2002 - "Yamanouchi is developing conivaptan, an orally active vasopressin V1A and V2 antagonist for the potential treatment of heart failure, edema and hyponatremia. "
|1.||Vasopressin Receptors (Arginine Vasopressin Receptor)
|6.||Arginine Vasopressin (Argipressin)
|7.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)